Has Brittany Case, MD received payments from drug or device companies?

Yes. Drug and device makers reported $17,104 in general payments to Brittany Case, MD across 774 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Brittany Case, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Brittany Case, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Brittany Case, MD

Medical Oncology · Daphne, ALNPI 1033537154

Payments from drug & device makers

$17,104in general payments, 2019–2025

Across 774 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$2K
Novartis$2K
AstraZeneca$1K
Johnson & Johnson$1K
Bristol Myers Squibb$809
Lilly USA, LLC$766
plus $10K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	41	$1,643
Novartis	64	$1,633
AstraZeneca(2 entities)	52	$1,140
Johnson & Johnson(2 entities)	64	$1,094
Bristol Myers Squibb	37	$809
Lilly USA, LLC	41	$766
Merck	36	$762
Amgen	25	$577
Genentech USA, Inc.	28	$530
Astellas Pharma US Inc	16	$516
Daiichi Sankyo Inc.	23	$505
Incyte Corporation	30	$496
Eisai Inc.	23	$432
Pfizer	27	$431
Takeda Pharmaceuticals U.S.A., Inc.	13	$401
Regeneron Healthcare Solutions, Inc.	15	$378
AVEO Pharmaceuticals, Inc.	15	$342
Beigene USA, Inc.	10	$236
Beone Medicines USA, Inc.	5	$230
Sanofi	11	$225
AbbVie	9	$200
Bayer	10	$189
Gilead(2 entities)	9	$179
Blueprint Medicines Corporation	9	$174
Exelixis Inc.	8	$151
Array Biopharma Inc	7	$142
GSK	8	$142
Seagen Inc.	9	$136
Genentech, Inc.	1	$127
Ipsen Biopharmaceuticals, Inc	6	$117
Boehringer Ingelheim	4	$114
Deciphera Pharmaceuticals Inc.	5	$109
Tersera Therapeutics LLC	4	$104
Servier Pharmaceuticals LLC	7	$104
Taiho Oncology, Inc.	6	$100
Stemline Therapeutics Inc.	5	$97
Pharmacyclics LLC, An Abbvie Company	5	$94
ADC Therapeutics America, Inc.	4	$87
Puma Biotechnology, Inc.	5	$86
Sanofi-aventis U.S. LLC	1	$83
Alnylam Pharmaceuticals Inc.	4	$77
Karyopharm Therapeutics Inc.	3	$73
Progenics Pharmaceuticals, Inc.	3	$69
EMD Serono, Inc.	3	$63
Acrotech Biopharma Inc.	4	$59
Springworks Therapeutics, Inc.	3	$57
Tesaro, Inc.	4	$56
Coherus Oncology, Inc.	2	$55
Adaptive Biotechnologies Corporation	3	$53
Azurity Pharmaceuticals, Inc.	3	$50
Morphosys, US Inc.	3	$48
Syndax Pharmaceuticals, Inc.	2	$48
Genmab U.S., Inc.	2	$44
Jazz Pharmaceuticals Inc.	2	$43
Mirati Therapeutics, Inc.	2	$42
Heron Therapeutics, Inc.	1	$41
Octapharma USA, Inc.	2	$38
Macrogenics, Inc.	1	$38
Spectrum Pharmaceuticals Inc.	2	$37
Sobi, Inc	2	$36

How this compares

$17,104 in reported general payments places this provider in the 50th percentile of 30 medical oncology providers in Alabama.

See all medical oncology providers in Alabama →

Medicare billing

Part B allowed, 2024

$3,746,228

Medicare patients

643

Services billed

185,431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Daphne

Syed Abbas AliJasper$3M
Joelle HamiltonHomewood$2.2M
Sachin PaiMobile$2.1M
Marshall SchreederHuntsville$1.1M
Pranitha ProdduturvarMobile$910K
John DubayTuscaloosa$756K
Sunil RangarajanBirmingham$576K
James DaughertyFlorence$119K
Hemant PatelMuscle Shoals$61K
Johnny NacillaCullman$23K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →